Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) shares were down 4.8% on Monday . The company traded as low as $6.71 and last traded at $6.72. Approximately 256,819 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 1,323,244 shares. The stock had previously closed at $7.06.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright began coverage on Trevi Therapeutics in a report on Wednesday, May 28th. They set a "buy" rating and a $21.00 price target for the company. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of Trevi Therapeutics in a report on Tuesday, May 20th. D. Boral Capital restated a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, B. Riley restated a "buy" rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Trevi Therapeutics has a consensus rating of "Buy" and an average target price of $18.63.

Trevi Therapeutics Trading Down 9.8%

The stock has a market cap of $635.92 million, a P/E ratio of -14.58 and a beta of 0.59. The stock has a 50 day simple moving average of $6.26 and a 200 day simple moving average of $5.02.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Activity

In related news, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This represents a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 18.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its holdings in shares of Trevi Therapeutics by 14.5% during the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock valued at $110,000 after purchasing an additional 3,387 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Trevi Therapeutics by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after buying an additional 2,935 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after buying an additional 22,145 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics in the 4th quarter valued at $49,000. Finally, Rosalind Advisors Inc. lifted its stake in shares of Trevi Therapeutics by 41.7% in the 4th quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company's stock valued at $4,378,000 after acquiring an additional 312,500 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.